For the third time, the Icahn School of Medicine at Mount Sinai has earned the American Medical Association (AMA) Joy in Medicine™ distinction.
Mount Sinai investigators have developed a new approach for treating invasive bladder cancer without the need for surgical removal of the bladder, according to a study published in Nature Medicine in September.
Top rankings include Mount Sinai Morningside and The Mount Sinai Hospital, with stroke rehabilitation a standout program
Michael F. Murray, MD, Professor of Medicine at the Icahn School of Medicine at Mount Sinai, has been named the new System Chief of the Division of Genomic Medicine and the Clinical Director of the Institute for Genomic Health at Mount Sinai.
Researchers at the Icahn School of Medicine at Mount Sinai have been awarded a $10.2 million grant from the National Heart, Lung and Blood Institute of the National Institutes of Health to investigate risk factors for malignant arrhythmias in mitral valve prolapse.
Research conducted at Mount Sinai and Yale confirms long COVID is a biological disease by showing blood biomarkers that can predict who has it
In a study published online in CELL today, scientists at UCSF QBI, University College London and the Icahn School of Medicine at Mount Sinai reported breakthrough findings on convergent evolutionary mechanisms shared by COVID-19 variants, allowing them to overcome both adaptive and innate immune system barriers.
Seventy-five years after pioneering doctors at The Mount Sinai Hospital conducted the first hemodialysis treatment in the United States, the hospital is marking progress to date in a continuing medical education (CME) event on Monday, October 2. The event will be led by innovators in the field of nephrology.
New research from Mount Sinai identifies key molecules in blood and nasal passages that play a pivotal role in asthma development and progression
A team of leading clinicians, engineers, and neuroscientists has made a groundbreaking discovery in the field of treatment-resistant depression.
First systematic study of the subject finds that more than half of unsalaried community health care workers in dual-cadre programs experienced unfair treatment in the workplace
Mount Sinai study focused on Harlem preschools emphasizes the need for specialized health promotion programs in classrooms starting at an early age
The Icahn School of Medicine at Mount Sinai has agreed to an exclusive license option with GNOMX Corp. (GNOMX) for epigenetic diagnostic and prognostic technology for infectious diseases.
$13 million will fund a multidisciplinary, multi-institution team effort to develop stronger and more versatile vaccines
The National Cancer Institute has awarded the Icahn School of Medicine at Mount Sinai a $3.4 million grant to create a model that identifies the best prostate cancer treatment for people with HIV.
New method can predict risks of cardiovascular disease, mortality in sleep apnea patients
Researchers at the Icahn School of Medicine at Mount Sinai have identified the structure of a special transporter found in red blood cells and how it interacts with drugs.
Agreement aims to improve patient care and outcomes on a global scale
Insights could impact approach to managing and preventing condition in children.
Results from a large-scale clinical trial could increase usage of high resolution imaging for guiding interventional coronary procedures
Asian Americans have significantly higher exposure than other ethnic or racial groups to PFAS, a family of thousands of synthetic chemicals also known as “toxic forever” chemicals, Mount Sinai-led researchers report.
Mount Sinai study identifies most effective and safest outpatient labor induction methods, potentially reducing hospital stays and increasing hospital efficiency in use of resources
The Mount Sinai Health System was recognized today as an outstanding health care employer in New York, ranking in the top 15 on the prestigious Forbes list of “America’s Best-in-State Employers.”
Mount Sinai study among the first to show that drugs targeting the lung, rather than bacteria, may prevent staph infection in flu patients
Mount Sinai Health System announces a multi-year renewal of an exclusive partnership with the United States Tennis Association (USTA)
The best heart rate for burning fat differs for each individual and often does not align with the “fat burning zone” on commercial exercise machines, Icahn School of Medicine at Mount Sinai researchers report. Instead, the researchers said, clinical exercise testing—a diagnostic procedure to measure a person’s physiological response to exercise—may be a more useful tool to help individuals achieve intended fat loss goals. The study, which used a machine learning-based modeling approach, was published online today in Nutrition, Metabolism and Cardiovascular Disease.
Using a novel proteogenomic strategy and a variety of machine learning tools, investigators from the Icahn School of Medicine at Mount Sinai and colleagues have identified a 64-protein signature that may predict a subset of ovarian cancer patients who are unlikely to respond to chemotherapy. The multicenter study, published online August 3 in Cell, reports on a pioneering analysis of chemo-refractoriness in high-grade serous ovarian cancer (HGSOC). The work also implicates possible therapeutic targets for these patients.
The cardiovascular polypill, developed by the Spanish National Centre for Cardiovascular Research (CNIC) and the pharmaceutical company Ferrer, has been included by the World Health Organization (WHO) in its List of Essential Medicines.
The Mount Sinai Medical Legal Partnership (MSMLP), which provides legal aid to Mount Sinai Health System patients in need, has launched a clinic to help breast cancer patients navigate legal issues that arise due to their diagnoses.
Human cells are constantly communicating, and some cells, particularly in cancer, are master manipulators, using these communications channels to persuade innocent bystander cells to collude and participate in tumor growth.
Psychosocial stress profoundly affects people’s lives globally, not least because it can be a critical risk factor for cardiovascular disease. Thanks to an $11.5 million award renewal from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, distinguished researchers at the Icahn School of Medicine at Mount Sinai and elsewhere aim to gain a deeper understanding of how stress influences cardiovascular health.
Investigators at the Icahn School of Medicine at Mount Sinai have designed an innovative RNA-based strategy to activate dendritic cells—which play a key role in immune response—that eradicated tumors and prevented their recurrence in mouse models of melanoma.
Cigarette smokers have higher odds of tobacco dependence than those who vape or use a variety of types of tobacco products, according to a Mount Sinai study published in July in Nicotine & Tobacco Research.
An Icahn School of Medicine at Mount Sinai study sheds light on the intricate interplay between mammary adipose (fat) tissue and breast health, and offers exciting possibilities for understanding breast development, lactation, cancer, and obesity and related metabolic disorders.
The Icahn School of Medicine at Mount Sinai will help lead and launch the first clinical trial focusing on women and minority populations to determine which coronary revascularization procedure best improves their survival and quality of life.
Babies are more likely to be born prematurely when either their father or mother has had a psychiatric diagnosis, according to a study.
The Icahn School of Medicine at Mount Sinai in New York, NY is pleased to announce that CastleVax, Inc. has completed enrollment and a preliminary analysis of a phase 1 trial of its licensed Newcastle disease virus (NDV)-based COVID-19 booster vaccine.
Findings may help inform the development of intervention and prevention strategies
The Lasker Foundation announced today that Salman E. Qasim, PhD, a postdoctoral fellow at the Icahn School of Medicine at Mount Sinai, is among five winners of its 10th annual Lasker Essay Contest.
Understanding the causes of this neurodevelopmental disorder is important to the development of new precision medicine therapies.
Data scientists at the Icahn School of Medicine at Mount Sinai in New York and colleagues have created an artificial intelligence model that may more accurately predict which existing medicines, not currently classified as harmful, may in fact lead to congenital disabilities. The model, or “knowledge graph,” described in the July 17 issue of the Nature journal Communications Medicine, also has the potential to predict the involvement of pre-clinical compounds that may harm the developing fetus. The study is the first known of its kind to use knowledge graphs to integrate various data types to investigate the causes of congenital disabilities.
Study represents a major milestone toward health equity for underrepresented populations in Alzheimer’s disease research
The Mount Sinai Morningside nursing teams and staff of the Cardiac Catheterization Lab and Unit 8E have received the Gold-level and Silver-level Beacon Award for Excellence from the American Association of Critical-Care Nurses.
Mount Sinai Queens today announced the opening of a new cardiac catheterization lab that will provide rapid and comprehensive care to hundreds of heart patients every year for life-threatening emergencies and scheduled cardiac procedures.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right